Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999990 | 0.86 | CYP19A1 (0.40) | KCNN4KIF11CYP19A1 | |
| SCHEMBL5999958 | 0.85 | RAB9A (0.39) | CYP17A1CYP11B1KIF11USP2RAB9A | |
| SCHEMBL6000278 | 0.82 | MAPK14 (0.40) | CYP3A4KIF11RAB9AKMT2A | |
| SCHEMBL5999951 | 0.81 | USP2 (0.55) | CYP17A1KIF11CYP19A1USP2RAB9A | |
| SCHEMBL5999709 | 0.81 | KIF11 (0.49) | KCNN4KIF11 | |
| SCHEMBL5999440 | 0.81 | CA1 (0.38) | CYP11B1CYP11B2KIF11RAB9A | |
| SCHEMBL6000276 | 0.81 | CYP19A1 (0.43) | KIF11CYP19A1KMT2A | |
| SCHEMBL5998796 | 0.80 | KCNN4 (0.42) | KCNN4CYP17A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL6000325 | 0.79 | CYP17A1 (0.39) | KCNN4CYP17A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL26278660 | 0.75 | NR3C1 (0.43) | KCNN4CYP17A1CYP3A4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | KCNN4 348/4885CYP17A1 4384/4885CYP3A4 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.